cell
The first CRISPR therapy approved in the U.S. will treat sickle cell disease
U.S. patients with sickle cell disease now have a novel treatment option: the first-ever CRISPR-based therapy. On December 8, the U.S. Food and Drug Administration approved the gene-editing therapy for use in patients age 12 years and older. In addition to offering hope of relief for people with severe forms of the painful blood disorder,…
A more effective experimental design for engineering a cell into a new state | MIT News
A strategy for cellular reprogramming involves using targeted genetic interventions to engineer a cell into a new state. The technique holds great promise in immunotherapy, for instance, where researchers could reprogram a patient’s T-cells so they are more potent cancer killers. Someday, the approach could also help identify life-saving cancer treatments or regenerative therapies that…